RxDoctor Payments Data

Brittany Wall

Family · Lexington, NCNPI 1639835432

Payments from drug & device makers

$3,228in general payments, 2019–2025

Across 189 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$623
  • Novo Nordisk$391
  • Pfizer$367
  • Lilly USA, LLC$317
  • Otsuka America Pharmaceutical, Inc.$177
  • Biohaven Pharmaceutical Holding Company Ltd.$124
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$3,215100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,228 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,398
Medicare patients
14
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol46$52,514
JardianceEmpagliflozin25$32,318
OzempicSemaglutide34$32,160
XareltoRivaroxaban27$27,735
LinzessLinaclotide36$24,177
TrulicityDulaglutide19$18,006
VraylarCariprazine Hcl12$16,670
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,518
MounjaroTirzepatide14$14,036
Breo ElliptaFluticasone/Vilanterol18$13,797
TrulancePlecanatide15$11,748
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,996
SymbicortBudesonide/Formoterol Fumarate22$7,061
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,098
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$110$79,20895 claims
AbbVieLinzess, Vraylar$623$40,84748 claims
Boehringer IngelheimJardiance$60$32,31825 claims
Novo NordiskOzempic$391$32,16034 claims
Lilly USA, LLCTrulicity, Mounjaro$317$32,04233 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$108$30,89247 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$105$11,74815 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$36$4,39211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.

Other family in Lexington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →